Table 3.
Imaging parameters in healthy controls and type 2 diabetic patients
| Controls (n = 10) | T2DM patients (n = 26) | P | |
|---|---|---|---|
| CMR | |||
| LVEDV, mL | 202 ± 36 | 209 ± 70 | 0.79 |
| LVESV, mL | 83 ± 18 | 117 ± 75 | 0.19 |
| LV mass, g | 123 ± 25 | 116 ± 27 | 0.51 |
| LVEF, % | 59 ± 4 | 47 ± 13 | <0.01 |
| DCE, g | 0 | 6.3 (0–11.3) | <0.01 |
| PET | |||
| MBF, rest, mL−1 min−1 g−1 | 0.75 ± 0.07 | 0.86 ± 0.19 | 0.02 |
| MBF, rest, corrected for RPP, mL min−1 g−1 | 1.22 ± 0.1 | 1.11 ± 0.4 | 0.20 |
| MBF, stress, mL min−1 g−1 | 2.64 ± 0.28 | 2.05 ± 0.65 | <0.01 |
| CFR | 3.54 ± 0.54 | 2.43 ± 0.79 | <0.01 |
| CFR, corrected for RPP, mmHg min−1 | 2.20 ± 0.35 | 1.97 ± 0.74 | 0.56 |
| External work, Joule | 1.26 ± 0.26 | 1.00 ± 0.31 | 0.04 |
| MVO2, mL g−1 min−1 | 0.09 ± 0.01 | 0.08 ± 0.01 | 0.23 |
| Myocardial efficiency, % | 32 ± 6 | 35 ± 9 | 0.39 |
Data are mean ± SD or median (interquartile range)
T2DM type 2 diabetes mellitus, CMR cardiac magnetic resonance, LVEDV left ventricular enddiastolic volume, LVESV left ventricular endsystolic volume, LVEF left ventricular ejection fraction, DCE delayed contrast enhancement, PET positron emission tomography, MBF myocardial blood flow, RPP rate pressure product, CFR coronary flow reserve, MVO 2 myocardial oxygen consumption